Beisler J A
J Med Chem. 1978 Feb;21(2):204-8. doi: 10.1021/jm00200a012.
The antitumor nucleoside, 5-azacytidine (5-AC), is best administered clinically by prolonged intravenous infusion to minimize toxic effects. In opposition to this administration technique is facile drug decomposition in aqueous formulations giving products of unknown toxicity. Analysis of 24-h-old water solutions of 5-AC with high-pressure liquid chromatography (HPLC) indicated a threefold mixture of 5-AC, N-(formylamidino)-N'-beta-D-ribofuranosylurea (RGU-CHO), and 1-beta-D-ribofuranosyl-3-guanylurea (RGU). Preparative HPLC allowed the isolation and subsequent identification of each component in the mixture, including RGU-CHO which until now has not been available for chemical and biological study. It was shown that RGU-CHO in water solution readily equilibrates to 5-AC and more slowly deformylates to give RGU irreversibly. The latter hydrolysis produce exhibited no pronounced toxicity when tested either in vitro or in vivo. Although RGU-CHO showed considerable antitumor activity against murine L1210 leukemia, hydrolysis studies indicated that all of the observed activity could be attributed to 5-AC formed by in vivo equilibration from RGU-CHO. Moreover, RGU-CHO seemed to impart to test animals a toxicity which was no greater than that anticipated from its ability to generate 5-AC.
抗肿瘤核苷5-氮杂胞苷(5-AC)临床上最佳给药方式是长时间静脉输注,以将毒性作用降至最低。与这种给药技术相反的是,该药物在水性制剂中容易分解,产生毒性未知的产物。用高压液相色谱法(HPLC)分析5-AC的24小时水溶液表明,其含有5-AC、N-(甲脒基)-N'-β-D-呋喃核糖基脲(RGU-CHO)和1-β-D-呋喃核糖基-3-胍基脲(RGU)的三倍混合物。制备型HPLC可分离并随后鉴定混合物中的每种成分,包括RGU-CHO,迄今为止该成分尚未用于化学和生物学研究。结果表明,RGU-CHO在水溶液中很容易平衡转化为5-AC,且更缓慢地脱甲酰基不可逆地生成RGU。后者的水解产物在体外或体内测试时均未表现出明显毒性。尽管RGU-CHO对小鼠L1210白血病显示出相当大的抗肿瘤活性,但水解研究表明,所有观察到的活性都可归因于RGU-CHO在体内平衡形成的5-AC。此外,RGU-CHO似乎给实验动物带来的毒性并不比其生成5-AC的能力所预期的毒性更大。